{"cord_uid":"p0z3zb4i", "sourcedb":"PMC", "sourceid":"PMC2705343", "divid":1, "text":"This retrospective study was approved by the local Ethics Committee. The local electronic database containing all patient diagnoses and discharge summaries of our rheumatologic outpatient clinic and the affiliated hospitals of the Department of internal medicine were searched for a combination of the terms of the rheumatologic/vasculitic/ connective tissue disease and pneumonia or pneumonitis. Each episode of a positive hit was reviewed. Severity of current immunosuppressive treatment was scored 0-4 as follows: 0 = no immunosuppressive medication; 1 = lowdose: (prednisone â‰¤ 10 mg/d) or (azulfidine/chloroquine); 2 = intermediate: (prednisone 20-40 mg/d) or (prednisone 10 mg/d+methotrexate) or (prednisone 10 mg/d+leflunomide) or (cyclosporine) or (pred-nisone+mycophenolate mofetil) or (prednisone 20 mg/ d+azathioprine); 3 = strong: (prednisone 40 mg/d+methotrexate) or (prednisone 20 mg/d+methotrexate+anakinra) or (prednisone 20 mg/ d+methotrexate+leflunomide) or (prednisone 20 mg/ d+etanercept) or (prednisone 40 mg/d+azathioprine) or (lower dose prednisone+azathioprine+leukopenia); 4 = maximal: (prednisone 60 mg/d+cyclophosphamide) or (prednisone 100 mg/d).", "project":"cdlai_CORD-19", "denotations":[]}